Intellia Therapeutics Named Edward Dulac Of Fate Therapeutics As CFO, Effective July 22, Succeeding Glenn Goddard
Intellia Therapeutics Named Edward Dulac Of Fate Therapeutics As CFO, Effective July 22, Succeeding Glenn Goddard
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024.
Intellia Therapeutics，Inc.（NASDAQ：NTLA）是一家领先的临床基因编辑公司，旨在通过CRISPR基因编辑技术革命性地改变医学。今天宣布任命爱德华·杜拉克为常务副总裁，首席财务官和司库，任期自2024年7月22日起生效。杜拉克先生将接替将于2024年6月30日卸任的格伦·戈达德。
Mr. Dulac is a highly accomplished biotechnology business leader and joins Intellia with more than 20 years of combined finance, business development and corporate strategy experience. Most recently, Mr. Dulac served as CFO of Fate Therapeutics. Prior to that role, Mr. Dulac spent numerous years at Celgene (now Bristol Myers Squibb), a leading global biopharmaceutical company, where he held multiple positions including as Vice President, Business Development & Strategy. Prior to Celgene, Mr. Dulac worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers and in corporate finance at Pfizer. Mr. Dulac holds a Bachelor of Pharmacy from the University of Pittsburgh and an MBA from Indiana University, Kelley School of Business.
杜拉克先生是一位经验丰富的生物技术业务领袖，具有超过20年的财务、业务发展和企业战略经验。最近，杜拉克先生担任Fate Therapeutics的首席财务官。在此之前，杜拉克先生在领先的全球生物制药公司Celgene（现为Bristol Myers Squibb）担任多个职位，包括副总裁、业务发展和战略。在Celgene之前，杜拉克先生在巴克莱资本和雷曼兄弟担任生物制药股票研究分析师，并在辉瑞担任企业融资工作。杜拉克先生获得匹兹堡大学药学学士学位和印第安纳大学凯利商学院MBA学位。